Global Central Lab Industry is anticipated to increase at an astounding 5.8% pace and reach US$ 4.5 Billion as a benchmark by 2033 | FMI

Global Central Lab Industry
Global Central Lab Industry

The Global Central Lab Industry is on a promising growth trajectory, according to a recent industry analysis. The market, valued at approximately US$2.42 billion in 2022, is expected to experience a robust Compound Annual Growth Rate (CAGR) of 5.8% from 2023 to 2033. This projected surge signifies a significant market expansion, with the market reaching a staggering US$4.47 billion by 2033, substantially surpassing the US$2.54 billion mark in 2023.

The significance of central labs in expediting pharmaceutical advancements cannot be overstated. By eliminating unnecessary stages, these labs enable pharmaceutical corporations to introduce novel substances to the market more swiftly. Moreover, central labs play a pivotal role in genetic testing services for a myriad of disorders, including but not limited to sickle cell anemia, Alzheimer’s, and Parkinson’s. The comprehensive services provided in central labs further aid in conducting clinical trials for new medications, contributing to the overall advancement of healthcare.

The evolution of the central lab industry is expected to receive a substantial boost over the projected period due to the increasing number of clinical trials. The prevalence of genetic illnesses has set a significant trend, leading to a surge in demand for private layers involved in the central lab sector.

Request For Sample Report Copy Uses Work Email To Get Quick Reply! 
https://www.futuremarketinsights.com/reports/sample/rep-gb-9067

In recent years, pharmaceutical and biopharmaceutical firms have entirely outsourced their research and development activities to central labs operated by private players. Besides lowering expenses for pharmaceutical and biotechnology businesses, central labs guarantee that findings are supplied more quickly and accurately.

Key Takeaways from the Global Central Lab Industry Study Report by FMI

  • The United States is the leading region, with almost 51% share of the total demand for central lab services generated worldwide in 2022.
  • Germany is the leading country in Europe that garnered almost 25% share of the total demand for central lab services in Europe in 2022.
  • The demand for central labs in the United Kingdom is poised to register a higher CAGR of 5.1% in Europe from 2023 to 2033.
  • China is the leading market in Asia, with a projected CAGR of 7.6% for its clinical central laboratory market from 2023 to 2033.
  • India is likely to follow China in demand for clinical trials with an annual growth rate of 6% during the forecast years.

Central labs are increasingly adopting cutting-edge technical solutions, which is helping the overall market to expand and is projected to continue. Correspondingly, the majority of central laboratories have fully automated their procedures, allowing them to save money and time,” opines Sabyasachi Ghosh, Associate Vice President at Future Market Insights (FMI).

Competitive Landscape for the Global Central Lab Industry Players

The overall market is fairly consolidated, as only some players successfully create a value chain by creating central labs at different locations. However, escalating government support in emerging economies following the pandemic is expected to encourage many new players to enter the market, intensifying competition.

Global Central Lab Industry  Key Companies Profiled

  • Covance (Labcorp)
  • Eurofins Global Central Library
  • PPD Central Lab
  • ICON Central Labs
  • Medpace Reference Laboratory
  • Q² Solutions
  • ACM Global Laboratories
  • Labconnect Inc.
  • Cerba Research
  • Medicover Integrated Clinical Services
  • Versiti Inc.
  • A.P. Møller Holding A/S
  • Ampersand Capital Partners
  • Lambda Therapeutics Research Ltd
  • Cirion Biopharma Research Inc.

Recent Developments by the Global Central Lab Service Providers

  • LabConnect Incorporate announced the expansion of its facilities in Johnson City in September 2020 to increase the production of clinical trial kits. This expansion has been planned to support the company’s rapid growth in the fields of immuno-oncology research and cell and gene therapy. The corporation is also expanding the storage capacity of its biorepository for specimens by moving its headquarters to Tennessee.
  • Labcorp or Covance Inc., a preeminent global life sciences company, declared that it was expanding its CB trial laboratory in June 2022. Its central laboratory is shared by a top Japanese provider of clinical laboratory testing services named BML. The company decided to expand existing laboratory capabilities in Japan to strengthen its central laboratory presence and drug development.

Click Here To Purchase Full the Report!
https://www.futuremarketinsights.com/checkout/9067

Key Segments Profiled in the Global Central Lab Industry Survey

By Service Type:

  • Genetic Services
  • Biomarker Services
  • Microbiology Services
  • Special Chemistry Services
  • Other Service Types

By End User:

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Academic and Research Institutes

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific Excluding Japan
  • Japan
  • The Middle East & Africa (MEA)

Author by:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these